187 related articles for article (PubMed ID: 30745277)
1. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
[TBL] [Abstract][Full Text] [Related]
2. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
[TBL] [Abstract][Full Text] [Related]
4. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
[TBL] [Abstract][Full Text] [Related]
5. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S; Njanpop Lafourcade BM; Ouangraoua S; Ouoba A; Kpoda H; Findlow H; Tall H; Seanehia J; Martin C; Ouedraogo JB; Gessner B; Meda N; Borrow R; Trotter C; Mueller JE
Clin Infect Dis; 2019 Jan; 68(3):435-443. PubMed ID: 30481265
[TBL] [Abstract][Full Text] [Related]
6. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
[TBL] [Abstract][Full Text] [Related]
7. Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.
Tang Y; Plikaytis BD; Preziosi MP; Borrow R
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S531-9. PubMed ID: 26553685
[TBL] [Abstract][Full Text] [Related]
8. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC
Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
[TBL] [Abstract][Full Text] [Related]
10. Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Tapia MD; Findlow H; Idoko OT; Preziosi MP; Kulkarni PS; Enwere GC; Elie C; Parulekar V; Sow SO; Haidara FC; Diallo F; Doumbia M; Akinsola AK; Adegbola RA; Kampmann B; Chaumont J; Martellet L; Marchetti E; Viviani S; Tang Y; Plikaytis BD; LaForce FM; Carlone G; Borrow R
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S514-20. PubMed ID: 26553683
[TBL] [Abstract][Full Text] [Related]
11. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
[TBL] [Abstract][Full Text] [Related]
12. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
[TBL] [Abstract][Full Text] [Related]
13. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
[TBL] [Abstract][Full Text] [Related]
15. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
[TBL] [Abstract][Full Text] [Related]
16. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
[TBL] [Abstract][Full Text] [Related]
17. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
Patel M; Lee CK
Cochrane Database Syst Rev; 2005 Jan; (1):CD001093. PubMed ID: 15674874
[TBL] [Abstract][Full Text] [Related]
18. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.
Trotter CL; Cibrelus L; Fernandez K; Lingani C; Ronveaux O; Stuart JM
Vaccine; 2015 Nov; 33(46):6212-7. PubMed ID: 26463444
[TBL] [Abstract][Full Text] [Related]
19. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448
[TBL] [Abstract][Full Text] [Related]
20. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
Karachaliou A; Conlan AJ; Preziosi MP; Trotter CL
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S594-600. PubMed ID: 26553693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
